We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Mutation Causes Lethal Condition in Infants

By LabMedica International staff writers
Posted on 05 Aug 2015
Protein losing enteropathy (PLE) is a condition of the gastrointestinal tract that results in loss of protein from the body, and often leads to severe abdominal swelling, malnutrition and early death in affected infants.

Whole-exome sequencing has been used to identify a nonsense mutation in the plasmalemma vesicle-associated protein gene that results in a distinct severe form of PLE characterized by hyperproteinemia, hypoalbuminemia, and hypertriglyceridemia.

Scientists at the Hospital for Sick Children (Toronto, ON, Canada) obtained samples from a patient with the PLVAP p.Arg358* mutation on two occasions during endoscopic investigation for severe PLE. More...
Control samples from the duodenum or colon were obtained from patients who were undergoing evaluation of gastrointestinal symptoms, among whom the endoscopic, histologic, and follow-up clinical impressions were normal.

Whole-exome sequencing was performed and the exome library preparation was performed using the Ion Torrent AmpliSeq RDY Exome Kit (Life Technologies; Carlsbad, CA, USA) and DNA quantified by Qubit DNA HS or BR assay (Life Technologies). The library was purified with Agencourt Ampure XT beads (Agencourt Bioscience; Beverly, MA, USA). Libraries were quantified by quantitative polymerase chain reaction (PCR) and sequenced on an Ion Torrent Proton Sequencer using a PI chip V2. The investigators used a variety of techniques for their study including flow cytometry read on a FACSCalibur (BD Biosciences; San Jose, CA, USA), confocal microscopy, histology and immunofluorescence.

The defect caused by mutations in PLVAP was due to increased leakage from small blood vessels rather than active loss from the cells lining the intestines. This finding is different from most cases of enteropathy, including the Microvillus Inclusion Disease and Congenital Tufting Enteropathy, which affect young children. In these latter conditions, genetic abnormalities cause cellular abnormalities primarily affecting intestinal epithelial tissue structure and function.

Abdul Elkadri, the lead study author, said, “These findings come at a critical time in medical science; the recent promise of gene therapy may make targeted correction of PLVAP mutations possible. In the meantime, we can use these findings to develop more rapid diagnostic strategies to screen infants for this genetic mutation and prevent severe complications at an early stage of the disease.” The study was published in the July 2015 issue of the journal Cellular and Molecular Gastroenterology and Hepatology.

Related Links:

Hospital for Sick Children
Life Technologies
Agencourt Bioscience




Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.